MyFinsight
Home
Blog
About
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,467K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
It represents the proceeds from ...
Changes in fair value of pre-fun...
Share-based compensation
Others
Negative Cash Flow Breakdown
Issuance cost
Decrease in accounts receivable
Purchase of property and equipme...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
Segment net loss
-7,312
4,918
-8,423
Depreciation
9
-16
23
Share-based compensation
624
-1,368
2,040
The amount of finance income (expenses), net
-12
-14
8
Changes in fair value of pre-funded warrants liability
-2,755
-
-
The amount represents of issuance cost
-116
-
-
Increase in other current assets
-46
-125
219
Decrease in accounts receivable
126
-
-126
Increase (decrease) in accounts payable
301
-258
84
Increase (decrease) in accrued liabilities and other operating liabilities
-15
-842
840
Net cash provided by (used in) operating activities
-3,464
2,447
-5,537
Purchase of property and equipment
3
-80
80
Net cash provided by (used in) investing activities
-3
80
-80
It represents the proceeds from issuance of ordinary shares warrants and pre funded warrants
10,000
-
-
Proceeds from issuance of common stock
0
-6,254
6,254
Issuance cost
171
-262
262
The amount represents proceeds from issuance of shares under collaboration agreement
0
-7,190
7,190
Proceeds from stock options exercised
-
130
-
Proceeds from warrant exercises
-
-354
354
It represents the exercise of warrants and options to ordinary shares
260
-
-
Net cash provided by (used in) financing activities
9,959
-13,406
13,536
Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation
6,492
-10,879
7,919
Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation
-8
-
29
Cash, cash equivalents and restricted cash and deposits at end of the period
16,688
16,688
8,740
Cash, cash equivalents and restricted cash and deposits at end of the period
18,526
-
-
Cash and cash equivalents, at carrying value
11,309
-
-
Restricted cash and cash equivalents
7,217
-
-
Cash, cash equivalents and restricted cash and deposits at end of the period
18,526
12,017
16,688
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
It represents the
proceeds from issuance of...
$10,000K
It represents the
exercise of warrants and...
$260K
Net cash provided by
(used in) financing...
$9,959K
Canceled cashflow
$171K
Cash, cash
equivalent, restricted...
$6,492K
Canceled cashflow
$3,467K
Issuance cost
$171K
Changes in fair value of
pre-funded warrants...
-$2,755K
Share-based compensation
$624K
Increase (decrease) in
accounts payable
$301K
The amount
represents of issuance cost
-$116K
Increase in other current
assets
-$46K
The amount of
finance income...
-$12K
Depreciation
$9K
Net cash provided by
(used in) operating...
-$3,464K
Net cash provided by
(used in) investing...
-$3K
Canceled cashflow
$3,863K
Segment net loss
-$7,312K
Purchase of property and
equipment
$3K
Decrease in accounts
receivable
$126K
Buy us a coffee